Cures Acceleration Network: BIO Strongly Supports the CAN Program
March 10, 2016
On behalf of the Biotechnology Industry Organization (BIO), I am writing to express our strong support for $500 million for Cures Acceleration Network (CAN) Act, a new initiative at the National Industries of Health (NIH) that was authorized in the recently-enacted Patient Protections and Afforadable Care Act.
Download Full Comments Below
FY 2011 CAN Letter (Senate) 0
Read BIO’s letter to the Senate Appropriations Committee
BIO and BIO members are urging lawmakers to enact a short-term extension of the MCM-PRV program while Congress is waiting to address a full reauthorization with PAHPA.
BIO has submitted comments to the Office of Science & Technology Policy on how regulations underpinning the Coordinated Framework for the Regulation of Biotechnology can better facilitate the use of biotechnology to stimulate the economy…
On behalf of the Biotechnology Industry Organization (BIO), I am writing to express our strong support for $500 million for Cures Acceleration Network (CAN) Act, a new initiative at the National Industries of Health (NIH) that was authorized in the recently-enacted Patient Protections and Afforadable Care Act.